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Abstract
Background: HPV4 is approved as a series of three timed doses expected to result in efficacy against specific HPV infections.
Completion rates in the US are quite low at the same time the structure of health care delivery is changing. The aim of this
study was to determine how the patient-, clinic- and systems-level characteristics facilitate or hinder the timely completion
of three HPV4 doses in both adolescent and adult female populations in a high-risk safety net population.
Methods: This is a retrospective study in which patient-, clinic- and systems-level data are abstracted from the electronic
medical record (EMR) for all females 10–26 years of age receiving at least one dose of HPV4 between July 1, 2006 and
October 1, 2009.
Results: Adults were more likely to complete the three dose series if they had at least one health care visit in addition to
their HPV4 visit, (aOR= 1.54 (95% CI:1.10, 2.15). Adults were less likely to complete the three dose series if they received their
second HPV4 dose at an acute health care, preventive care or postpartum visits compared to an HPV4-only visit (aOR= 0.31
(95% CI: 0.13, 0.72), 0.12 (0.04, 0.35), 0.30 (0.14, 0.62), respectively). Hispanic adults were less likely than whites to complete
the series (aOR= 0.24 (95% CI:0.10, 0.59). 39% of adolescents who completed two doses completed the series.
Conclusions: HPV4 is more likely to be effectively administered to adults in a safety net population if multiple health care
needs can be met within the health care system.
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Introduction
Cervical cancer has continued to decline in the US to 8.0/
100,000 because of Pap screening programs that depend on
colposcopy and excisional treatments [1]. The two prophylactic
human papillomavirus (HPV) vaccines, approved to prevent HPV
16 and 18, prevent, to various degrees and for uncertain durations,
two (HPV4) and seven (HPV2) oncogenic HPV types associated
with cervical cancer [2–4]. Both vaccines are efficacious in a three
dose regimen for reducing the incidence of cervical intraepithelial
neoplasia grade 3 (CIN 3), and the need for colposcopies and
excisional procedures [5].
HPV vaccination programs in the US indicate that while 53%
of 13–17 year old females have received at least one dose of
HPV4, only 37% of these have received three in a timely manner
[6]. Independent studies in settings including those with Medicaid
coverage, private insurance, closed health care systems and
university teaching systems also show low rates of completion
[7–25]. Three studies report the completion rates in safety net
health systems to be 12–28% [12,17,24].
Safety-net systems serve all ages of vulnerable, uninsured
Americans [26,27]. They are often publically funded and can be
either in urban cores or in rural settings. Examples include
Federally Qualified Health Centers (FQHC) whose purpose is to
enhance the provision of primary care services in these populations
[26]. The National Cancer Institute (NCI) Center to Reduce
Cancer Health Disparities (CRCHD) postulates that cervical
cancer is an indicator of larger health system concerns, a
bellwether for other health care vulnerabilities [27,28]. Hence,
optimizing HPV vaccine strategies in safety net health systems
may reduce the risk of cervical cancer and improve other health
care disparities [27,29,30].
The modified Andersen Behavioral Model [31,32] consists of
patient-, clinic- and systems-level characteristics that may influ-
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ence the behavior to complete three doses of HPV4 on time.
Patient-level characteristics that may predict decision making skills
about a vaccine to prevent a sexually transmitted infection include
age, race/ethnicity, prior pregnancy history, and prior abnormal
cytology screenings. Health seeking and decision making behaviors
of pediatric and adolescent females are often dominated by
parental influence and differ from health behaviors of independent
adult women. However, the effect of pregnancy or prior abnormal
cytology may mitigate the influence of age in decision making and
health seeking behaviors for HPV vaccination. In addition, the
health belief systems of different racial/ethnic cultures influence
the health decision making processes for cancer prevention [28].
Clinic-level characteristics may describe the intended purpose of
the health care visit. Within the behavioral model the intended
purpose of the health care visit will influence decision making at
the visit. The preventive health care visits root from a different
intention than acute care visits or follow up from acute care;
likewise, counseling visits, for any reason, engender a different
health intention than do visits linked to the delivery of an infant.
Understanding how these factors influence the decision to
complete an on-time three dose series may allow safety net health
systems to focus on vaccination attempts where they are most
likely to be successful with minimal resource wastage.
Influential systems-level characteristics are described by those
policies that determine overall clinic function. These include the
opportunity for repeated health care utilization, allowing multiple
health issues to be discussed during specific types of visits, and a
program to promote HPV4 vaccination where a standing order for
vaccination was in place to facilitate vaccination without a
physician visit.
Guided by this modified Andersen behavioral model of access to
health care and health systems utilization [31,32], we designed this
study to investigate the integration of the patient-, clinic-, and
systems-level characteristics within our safety-net health system on
the timely compliance of the HPV4 series completion among
adolescent and adult females prior to the approval of HPV2.
Results
Of the 27,786 females, aged 10–26 years, 1621 (5.8%) received
at least one dose of HPV4 and of those, 1563 had supporting
EMR documentation of vaccination (Figure 1). 651 (42%) females
received only one dose, 409 (26%) received only two doses, and
503 (32%) received three or more doses of HPV4. Women with
more than three doses (0.9%), or who were older than 26 years at
the time of their first vaccination were censored from further data
analysis.
Patient-level data revealed that 258 (17%) were 10–17 year
olds (adolescents) and 1305 (83%) were 18–26 year olds (adults)
(Table 1). Race/ethnicity was reported as 38% Black/50% White
in the adolescent group and proportionately reversed in the adult
group (57% Black/32% White). Nearly three quarters of all
females had at least one pregnancy prior to HPV4 vaccination,
including 6% of the 10–13 year olds; and 30% of those screened
had past abnormal cytology.
Clinic- and systems-level characteristics (Table 2)
showed that the first HPV4 dose was administered most often at
a HPV4-only visit for both age groups (52%). Thereafter, 14% of
the initiating doses among adolescents occurred equally at either a
preventive or postpartum visit; and, for adults, more often at a
postpartum visit than a preventive visit (24% vs. 10%, p,0.001).
Both concomitant vaccines (45%) and birth control prescriptions
(26%) were frequently received at the first HPV4 dose regardless of
age.
The second dose was most often received at a HPV4-only visit
for both age groups (74%) along with concomitant vaccinations
and birth control prescriptions: 59% and 24%, respectively, for
adolescents, and 22% and 41%, respectively, for adults.
Less than a third (503/1563) of the females initiating the HPV4
series completed three doses regardless of age. The final dose was
received most often at a HPV4-only visit (68%), followed by a
preventive health care visit (12%).
On-time Series Completion of Three Doses
The three dose series was completed, on average, within 30
weeks (95% CI: 29, 31) of initiating the series, regardless of age or
number of visits: 53% attended only the three HPV4 visits; 47%
attended, on average, 5.4 visits (95% CI: 5.2, 5.6). 18% of the
population took longer than one year to complete the three dose
series at an average of 83 weeks (95% CI: 80, 86).
Of the females who received three doses (Table 3), 68% (342/
503) received them within the recommended time intervals. Of
females receiving at least one HPV4 dose, more adolescents than
adult women completed the series on time (29% (74/258) vs. 21%
(268/1305), p = 0.004), but among those receiving at least two
doses, adolescents and adults equally completed the series (39.4%
(74/188) vs. 37.0% (268/724)). Predicting receipt of the second
dose within the series was only dependent on patient-level
characteristics: black adolescents were less likely than white
adolescents (OR = 0.27 (95% CI: 0.11, 0.71)); and older adults
(22–26 yrs) were more likely than younger adults (18–21 yrs)
(OR = 1.80 (95% CI: 1.16, 2.79)).
Completion of three on-time doses among those receiving at
least one dose occurred at equal frequencies within the dichoto-
mized adolescent and adult age groups. For adolescents there was
no difference in on-time completion rates between the younger
10–13 year olds and the older 14–17 year olds (36.5% (19/52) vs.
26.7% (55/206)); and for adults, there was no difference in on-time
completion rates between younger 18–21 year olds and older 22–
26 year olds (20.1% (114/568) vs. 20.9% (154/737)).
The visit type at which HPV4 was received was dominated by
HPV4-only visits among on-time completers. Subsequently, the
first HPV4 dose was received at preventive visits in 24% of
adolescents and 15% of adults. The third on-time HPV4 dose was
received at an acute visit in 10% of adolescents. In adults, the third
on-time HPV4 dose was received equally among all visit types,
except the postpartum visit. No person completed the third dose
on-time at a postpartum visit.
For on-time completers, the frequency of concomitant vaccina-
tions was significantly higher among adolescents (15%) than adults
(2%) with the first HPV4 dose (p,0.001); and was significantly
higher at the first than at any other HPV4 dose (p,0.001).
Prescriptions were provided equally to adolescents (15%) and
adults (14%); and for both ages combined, equally at the initiating
(14%) and completing doses (13%). Very few prescriptions or
concomitant vaccinations were provided at the second HPV4
dose.
Among all females who received at least two doses, age did not
predict on-time series completion (Table 4). Other patient-,
clinic- and systems-level characteristics in the adolescent age group
influenced the likelihood of completing three HPV4 doses on-time
when considered singly, but, in the adjusted analysis no model-
based characteristics predicted adolescent on-time HPV4 comple-
tion.
In adult women, the adjusted analysis for on-time HPV4
completion was influenced by the model-based characteristics.
Specifically, the receipt of other health care between HPV4 doses
and the opportunity to receive HPV4 without a physician visit
On-Time Compliance with HPV4 in Safety Net Systems
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were significant predictors of on-time completion. Additionally,
white women were more likely than Hispanics, and nulliparous
women were more likely than multiparous women to complete the
three dose series on-time.
Discussion
This study was conducted in a safety net health system with
patients at high risk for adverse health outcomes at earlier ages,
including cervical cancer [27,28], as evidenced by 30% of the
population already having an abnormal Pap test prior to
vaccination. A conceptual framework was used to identify
patient-, clinic- and systems-level factors’ influence on behavior
to complete the vaccine series. As seen in other underserved
populations [12,17,24], our rate of on-time adolescent and adult
three-dose completion is lower than national data [10,33].
Our results are the first to show the association between the
systems-level policies and on-time HPV4 series completion.
Several studies have indicated that a regular source of health
care, even among federally qualified health centers (FQHCs)
which resemble our safety-net system [29,30], results in better
health prevention outcomes. In addition our results are the first to
show among those receiving care in a safety-net population that
Figure 1. CONSORT diagram of HPV4 recipients in safety net health system.
doi:10.1371/journal.pone.0071295.g001
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standing order policies which facilitated receipt of the second
HPV4 dose without a physician visit were successful.
In both the adolescent and adult populations our first HPV4
doses were administered much more frequently at HPV4-only
visits than reported in a university based health care system, but
the second and third doses were administered at HPV4-only visits
at similar frequencies [18,19]. Our results differ from others,
though, in that the HPV4-only visit type, especially at the second
HPV4 dose, was significantly influential in facilitating our adults to
complete the series on-time; however, it had no significant
influence on adolescent vaccine completion [18].
Our adolescent results showed a higher association between
receiving other concomitant vaccines and the first HPV4 dose
versus the second or third HPV4 dose, as shown by Dempsey [18].
Nonetheless when our results were adjusted for patient-, clinic-and
systems-level characteristics, concomitant vaccinations did not
significantly influence our on-time adolescent completion of the
series. This is a disappointment, especially for the high risk safety
net population, as the new adolescent platform of vaccines recently
recommended by the Advisory Committee on Immunization
Practices (ACIP) was meant to reinforce adolescent health care
[34,35].
Patient-level characteristics variously studied by others to
predict three dose completion rates are parity, race, and age [8–
25]. While HPV vaccination is recommended prior to the onset of
sexual activity because sexual activity is the most common
mechanism of HPV infection [5], virginity has not been shown
to be a predictor of completing a three dose HPV4 series. Parity,
though, is a strong predictor of not completing a three dose series
among 18–26 year old women [13] as our data corroborated.
The influence of race is unclear in the literature, and probably
not significant given the wide range of evidence for racial influence
on three dose HPV4 completion. Among adolescents in popula-
tions similar to our safety net population, Perkins [17] showed that
race was not a predictor when considering white, black and
Hispanic races; but Cook’s [12] results indicated that black
adolescents were less likely than white adolescents to complete the
HPV4 series. In other insured populations, white adolescents were
more likely to complete the HPV4 series than black or Hispanic
adolescents [9,11,13–15,18,20,21,23]. Our results, in our safety
net population, indicated that white, black and Hispanic
adolescents were equally likely to complete three HPV4 doses
on-time.
No studies in safety net populations have documented the
influence of race on adult completers of the HPV4 series. In
various insured adult women populations, race was neither
predictive of three dose completion [13] nor more likely for white
adults than black or Hispanic adults [14,15,19,23]. Our results
indicate that Hispanic women in a safety net population are less
likely to complete the three HPV4 doses on-time than white
women, but this may be due to the imbalanced racial outreach in
our health care system and not intrinsic to Hispanic women.
The age at which to initiate HPV4 has been vociferously
debated in the US. Based on the efficacy and immunogenicity data
submitted to the FDA for regulatory approval, HPV4 has minimal
efficacy if given to those already seropositive for the vaccine-
relevant HPV types [36] and inferior antibody titer induction
when given in less than three doses [37–39]. The CDC
recommendation of targeting 11–12 year olds for vaccination
assumes this is the optimal age range for HPV vaccine efficacy due
to HPV naivety. But even at this young age, HPV naivety is not
guaranteed. Up to 7% of females report having sex before age 13,
8% of 9th grade US females (14–15 years) report being forced to
have sex, and on average 29% of 9th graders have ever had sex
[40]. Other CDC studies show that 10–15% of children from birth
through 13 years of age test positive for oro-and anogenital high-
risk HPV type infections [5,41,42]. Moving the age of vaccination
younger or even to infancy risks waning of vaccine efficacy prior to
the age range at which HPV prevalence is the highest, 16–25 years
[43].
From the opposite perspective, another prevention strategy to
ensure effectiveness during the time of highest exposure is to move
Table 1. Descriptors of the Vaccinated Population.
10–13 year olds 10–17 year olds{ 18–26 year olds
N=52 N=258 N=1305
Age, mean (SD) 11.8 (1.0) 15.2 (2.0) 22.0 (2.4)
Race/ethnicity, n (%)
White 34 (65%) 129 (50%) 418 (32%)
Black 11 (21%) 97 (38%) 739 (57%)
Hispanic 3 (6%) 19 (7%) 98 (7%)
Other 4 (8%) 13 (5%) 50 (4%)
Obstetrical History* N= 243 N= 1225
Gravidity, n $1 (%) 3 (6%) 102 (42%) 974 (80%)
Parity, n $1 (%) 3 (6%) 91 (37%) 927 (76%)
Obstetrical History* N= 52 N= 243 N= 1225
Gravidity, mean (95% CI) 0.06 (20.008, 0.123) 0.52 (0.432, 0.613) 1.64 (1.555, 1.712)
Parity, mean (95% CI) 0.06 (20.008, 0.123) 0.42 (0.346, 0.494) 1.26 (1.202, 1.320)
Pap cytology* n (%) N= 0 N= 63 N= 1033
Abnormal – 13 (21%) 317 (31%)
{There were no 9 year olds who received HPV4 in this study. The demographics of the 10–13 year olds were highlighted from the adolescent age group patient-level
characteristics because they are a broad CDC target group for HPV vaccination.
*Documented at any time prior to the first HPV4 dose.
doi:10.1371/journal.pone.0071295.t001
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HPV4 initiation to older adolescents or young adult females; this
constitutes the ACIP ‘catch-up’ immunization recommendation.
Immunizing at 15 years instead of 12 provides greater cervical
cancer prevention for the first 50 years of vaccination assuming
that 70% of 15 year olds complete the three doses on-time [44].
This is the most common practice pattern to date in the US [45]
despite knowing that by 18 years of age, 64% of females have had
a sexual experience, and 23% have had sex with four or more
partners [40].
Determining the age of HPV4 initiation, thus, becomes a cost
effectiveness question. While no health economic models have
directly used compliance with three doses as a modeling
parameter, population coverage could be seen as a proxy for
dosing compliance. For example, should 70% of the naı¨ve
population receive all three doses appropriately, 70% population
coverage would be established. If only 50% of this covered
population actually completed all three doses on-time, the effective
population coverage would drop as low as 35%. Health care
models show that the cost effectiveness of HPV4 vaccination
wanes dramatically as population coverage diminishes [46].
Hence, timely dosing of the series becomes as important to the
health care economics of this primary prevention program as the
pivotal parameters of duration of vaccine efficacy and for how
many HPV types the female was seronegative at the time of
vaccine initiation [47,48]. If one age range results in significantly
inferior three dose completion rates, then the cost-effectiveness of
this primary prevention strategy could be compromised.
Nelson’s work [49] shows that for the Hepatitis B vaccine, a
similar three dose series, the likelihood of completing the three
doses decreases as the age of initiation advances beyond 5 years.
For HPV4, several studies show that among adolescents, those
younger than 15 years have higher completion rates than older
adolescents [11,12], while other studies show older adolescents are
more likely to appropriately complete the HPV4 series than the
pre-pubescents ([8–10,23]. Still others show that there is no
difference in completion rates by adolescent age of HPV4
initiation [16–18,20,22,24]. Our study showed that in a safety
net population there was no difference in completion rates
between younger and older adolescents.
The same diffuse pattern is seen for adolescent vs. adult
completion rates with adolescents more likely to complete the
series in some studies [10,15,16]; adults more likely to complete
the series in other studies [13,14,23] and some studies showing
that neither age group is more likely than the other to complete the
series [17,19,21]. Our study showed that in a safety net
population, adolescents were more likely than adults to complete
the second dose in the series leading to a higher overall completion
rate, with white race being the only predictor of second dose
completion among adolescents.
Within adult age ranges, while our study supported the
literature [19] that age did not predict three dose completion
rates, we did show that 22–26 year old women were more likely
than 18–21 year old women to complete the second dose in the
series. Completing the third dose critically depended on the clinic-
and systems-level events at the second dose, leading us to conclude
that health care access for all medical needs within a safety net
population is more important for complete on-time three dose
HPV4 vaccination than the age at which the series is initiated.
Limitations of the Study
There are several limitations to our study. Our safety net health
care system may not be generalizable to other safety net systems,
nor to other health care systems with a broad payor mix.
Table 3. Timely Series Completion by Visit Type at Each HPV4 Dose.
On-Time Three Dose Series Completion*
First HPV4 Dose Second HPV4 Dose Third HPV4 Dose
10–17 yrs 18–26 yrs All women 10–17 yrs 18–26 yrs All women 10–17 yrs 18–26 yrs All women
N=74 N=268 N=342 N=74 N=268 N=342 N=74 N=268 N=342
Preventive 18 40 58 3 4 7 4 20 24
(24%) (15%) (17%) (4%) (1%) (2%) (5%) (7%) (7%)
Acute visit 6 34 40 3 8 11 7 15 22
(8%) (13%) (12%) (4%) (3%) (3%) (10%) (6%) (6%)
Follow up visits 4 9 13 3 9 12 3 14 17
(5%) (3%) (4%) (4%) (3%) (4%) (4%) (5%) (5%)
Postpartum 6 37 43 1 9 10 0 0 0
(8%) (14%) (13%) (1%) (3%) (3%) – – –
Other visits 5 11 16 1 17 18 3 21 24
(7%) (4%) (5%) (1%) (6%) (5%) (4%) (8%) (7%)
HPV4-only 35 137 172 63 221 284 57 198 255
(47%) (51%) (50%) (85%) (82%) (83%) (77%) (74%) (74%)
Prescriptions 11 38 49 3 20 23 9 35 44
(15%) (14%) (14%) (4%) (7%) (7%) (12%) (13%) (13%)
Other Vaccinations 11 6 17 3 3 6 1 3 4
(15%) (2%) (5%) (4%) (1%) (2%) (1%) (1%) (1%)
*Dosing intervals: dose 1–2$4 weeks but #26 weeks; dose 2–3$12 weeks; and dose 1–3$24 weeks but #52 weeks.
doi:10.1371/journal.pone.0071295.t003
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Table 4. Predictors of On Time Series Completion by Patient-, Clinic- and Systems-Level Characteristics.
Receipt of On-Time Three Dose Series*
Crude OR (95% CI) Adjusted1 OR (95%CI)
10–17 yrs 18–26 yrs 10–17 yrs 18–26 yrs
N=188 N=724 N=180 N=683
Age (yrs){ 0.93 (0.81, 1.07) 1.02 (0.96, 1.09) 11 11
Race/ethnicity{
White Referent Referent Referent Referent
Black 0.39 (0.20, 0.74) 0.87 (0.62, 1.21) 0.62 (0.28, 1.33) 11
Hispanic 0.30 (0.08, 1.18) 0.19 (0.08, 0.45) 11 0.24 (0.10, 0.59)
Other 0.08 (0.01, 0.60) 1.37 (0.66, 2.85) 0.05 (0.01, 0.48) 11
Gravidity{ N=180 N= 683 N=180 N= 683
G= 0 Referent Referent Referent Referent
G.0 0.46 (0.24, 0.88) 0.45 (0.32, 0.64) 0.32 (0.04, 3.01) 1.41 (0.58, 3.46)
Parity{ N=180 N= 683 N=180 N= 683
P = 0 Referent Referent Referent Referent
P.0 0.52 (0.27, 1.00) 0.41 (0.29, 0.57) 2.18 (0.24, 20.17) 0.34 (0.15, 0.81)
Visit Type for dose 1 visit
HPV4-only Referent Referent Referent Referent
Preventive 3.27 (1.40, 7.68) 1.34 (0.84, 2.11) 2.11 (0.79, 5.68) 11
Acute Visit 1.50 (0.48, 4.66) 1.61 (0.97, 2.68) 11 11
Follow up 4.00 (0.70, 22.91) 1.80 (0.70, 4.65) 11 11
Postpartum 0.67 (0.24, 1.83) 0.66 (0.43, 1.02) 11 11
Other Health Needs 2.00 (0.54, 7.37) 2.83 (1.07, 7.48) 11 1.46 (0.50, 4.25)
Visit Type for dose 2 visit
HPV4-only Referent Referent Referent Referent
Preventive 0.59 (0.15, 2.38) 0.19 (0.07, 0.55) 11 0.12 (0.04, 0.35)
Acute Visit 0.83 (0.19, 3.60) 0.44 (0.20, 1.00) 11 0.31 (0.13, 0.72)
Follow up 4.14 (0.42, 4.76) 0.83 (0.36, 1.93) 11 11
Postpartum 0.15 (0.02, 1.24) 0.23 (0.11, 0.48) 11 0.30 (0.14, 0.62)
Other Health Needs 0.28 (0.03, 2.42) 0.84 (0.45, 1.57) 11 11
Non-HPV4 visits between first and last dose
None Referent Referent Referent Referent
$1 non-HPV4 visit 0.65 (0.35, 1.23) 1.61 (1.19, 2.18) 11 1.54 (1.10, 2.15)
Other vaccinations at dose 1 visit
None Referent Referent Referent Referent
$1 other vaccination type 3.14 (1.10, 8.91) 0.67 (0.26, 1.76) 2.66 (0.75, 9.42) 11
Other vaccinations at dose 2 visit
None Referent Referent Referent Referent
$1 other vaccination type 0.92 (0.21, 3.98) 0.29 (0.09, 1.01) 11 11
Other Prescriptions at dose 1 visit
None Referent Referent Referent Referent
$1 other prescription 1.82 (0.73, 4.52) 1.93 (1.19, 3.13) 11 1.54 (0.87, 2.71)
Other Prescriptions at dose 2 visit
None Referent Referent Referent Referent
$1 other prescription 2.37 (0.39, 14.51) 0.74 (0.43, 1.28) 11 11
*Among women with two or more doses and with complete data. Appropriate dosing interval means: the interval between dose 1 and dose 2$4 weeks but#26 weeks,
and the interval between dose 2 and dose 3$12 weeks, and the interval between dose 1 and dose 3$24 weeks but #52 weeks.
1Adjusted for significant variables in the univariate model.
11Variable was not significant in the univariate model.
{Visit at which the first dose of HPV4 was initiated.
Bold font indicates Odds Ratios are statistically significant compared to referent.
doi:10.1371/journal.pone.0071295.t004
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The initiation rate of HPV4 was very low in our institution;
hence, those females that did choose to initiate may not be
generalizable to the entire safety net population in enthusiasm for
completing the series on time. The adolescents served by the TMC
health care system may not be generalizable to other pediatric
populations in that they are more representative of the safety net
population of the uninsured, vulnerable and disenfranchised.
In addition, the on-time series completion rates may currently
be worse than this study indicates. This study described the use of
HPV4 at a time of high use, immediately after its approval and
during the heavy public advertisement campaigns that ensued. In
addition, even though it is unlikely given the catchment area and
safety net nature of our population, females may have received
other HPV4 doses at other health care facilities that we were
unable to capture.
Methods
This research was approved by the TMC Privacy Board and by
the UMKC Adult Health Sciences Institutional Review Board as
an exempt study not requiring individual consent (#11–16e).
The electronic medical record (EMR) and billing records of
Truman Medical Center (TMC) identified all office visits of
females whose ages were between 9 and 26 years and who were
seen between July 1, 2006 and October 1, 2009. No 9 year olds
received HPV4, making our study age range from 10–26 years.
The TMC population is a safety net population [26,50] of
vulnerable uninsured, underinsured and low income patients who
seek care in the health care system associated with the teaching
service of the University of Missouri-Kansas City School of
Medicine; this system is located both in the urban core and in a
rural setting at the outer Eastern border of Kansas City, Missouri.
Among this set of women, all visits coded for HPV4 vaccination
were identified and cross referenced with the vaccine log
maintained in the clinic.
Functionally, all data were manually abstracted from the EMR.
Patient-level data included age at first HPV4 dose which was
recorded as a continuous variable and dichotomized to 10–17 year
and 18–26 year groups, mirroring the ages for adolescent and
adult abilities to make health care decisions as well as the
recognized age of consent for medical care. Race/ethnicity was
self-identified in the registration files of the EMR, and coded as
White, Black, Hispanic or Other. Gravidity and parity were
defined at the first HPV4 dose. Any cytology screening history was
recorded through the first HPV4 dose.
Clinic-level data included the date of visit and visit type. The
visit type was inferred from the visit note by agreement of two
authors, and classified as preventive, acute or follow up from an
acute visit, as well as postpartum or any ‘other’ health care visit.
Preventive well woman or well child exams included school, sports
or work physicals and visits without symptomatic complaints. An
acute health care visit was defined as a visit for which a specific
health outcome would be addressed such as a new onset illness, a
colposcopy or loop electrosurgical excision procedure (LEEP).
Follow up for acute health care visits documented the health
services rendered subsequent to an acute visit including women in
follow up for abnormal cytology. Postpartum visits included those
women who received a dose of HPV4 at any time after delivery up
to and including the 6 week visit. Other health care visits included
counseling visits (e.g. smoking cessation, depression, or contracep-
tive counseling).
The systems-level visit data included health care visits for more
than HPV4 vaccination; the administration of HPV4 without a
concomitant physician visit (HPV4-only visit type); and whether
other vaccinations or prescriptions were provided at the visit.
Other vaccinations given included TDaP (tetanus, diphtheria and
acellular pertussis), Td (tetanus and diphtheria), Hepatitis A,
Hepatitis A and Hepatitis B combination, seasonal flu vaccine,
meningitis (MCV4) vaccine, MMR (measles, mumps and rubella),
or varicella virus vaccine. Other prescriptions included topical,
oral, vaginal or rectal medications. These characteristics were
recorded starting with the first dose of HPV4 and included each
health care visit until the last dose of HPV4 was given or 12
months elapsed.
Appropriate time intervals between doses were defined as the
interval between dose 1 and dose 2$4 weeks but #26 weeks; the
interval between dose 2 and dose 3$12 weeks; and, the interval
between dose 1 and dose 3$24 weeks but #52 weeks as defined
by the Centers for Disease Control and Prevention (CDC) and
comparative dose schedules for optimal immunologic response
[37–39,51,52,53].
Statistics
Chi-square and Student’s t tests were 2 sided using an alpha of
0.05 with Bonferroni corrections for multiple comparisons. A
backward stepwise logistic regression was used to determine which
patient-, clinic- and systems-level variables were significant for the
outcome using p,0.10 for entry and p,0.05 for significance. All
data analyses were performed using SPSS version 18.0 [54].
Conclusions
Completion of three on-time doses of HPV4 is most influenced
by health care access for all medical needs, and is independent of a
woman’s age and independent of the type of visit at which she is
offered the initial vaccination. Improving the cost effectiveness of
cervical cancer prevention may include emphasizing to HPV4
recipients the importance of completing all three doses on time.
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